Breast Cancer Vaccine Market Breast Cancer Vaccine Clinical Pipeline Report 2022

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

What are Cancer Vaccines?

Mechanism of Cancer Vaccines
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

Mechanism of Breast Cancer Vaccine
3.1 Principle Strategies for Eliciting Immune System
3.1.1 Overcoming Immune Suppression
3.1.2 Modulation of Immune Checkpoints
3.2 Immunogenicity and Responses to Therapies
3.3 Breast Cancer Therapeutic Vaccines

Global Breast Cancer Incidence
4.1 US
4.2 Europe
4.3 Asia
4.4 Rest of the World

Global Breast Cancer Vaccine Market Current Scenario
5.1 Unexplored Opportunity
5.2 Global Breast Cancer Vaccine Pipeline Overview

Need for Personalized Breast Cancer Vaccines

Global Breast Cancer Vaccine Market Dynamics
7.1 Favorable Parameters
7.2 Commercialization Challenges

Global Breast Cancer Vaccine Market Future Prospects

FDA Guideline for the Development and Marketing of Cancer Vaccines
9.1 Considerations for Both Early and Late Phase Clinical Trials
9.1.1 Patient Population
9.1.2 Monitoring The Immune Response
9.1.3 Biomarkers As Evidence Of Efficacy
9.1.4 Adjuvants Used To Stimulate Immune Response
9.1.5 Multi-Antigen Vaccines
9.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
9.1.7 Concomitant And Subsequent Therapies
9.2 Considerations for Early Phase Clinical Trials
9.2.1 Starting Dose And Dosing Schedule
9.2.2 Booster And Maintenance Therapy
9.2.3 Dose Escalation
9.2.4 Single-Arm Versus Randomized Phase 2 Trials In Early Development
9.3 Considerations For Late Phase Clinical Trials
9.3.1 Safety Profile From Early Phase Clinical Trials
9.3.2 Endpoints
9.3.3 Statistical Issues
9.3.4 Control Issues
9.3.5 Delayed Vaccine Effect
9.3.6 Autologous Vaccine Trials
9.3.7 Accelerated Approval Regulations

Global Breast Cancer Vaccine Clinical Pipeline by Company and Phase
10.1 Preclinical
10.2 Phase-I
10.3 Phase-I/II
10.4 Phase-II
10.5 Phase-II/III
10.6 Phase-III

Discontinued and Suspended Breast Cancer Vaccine in Clinical Pipeline by Company and Phase
11.1 Suspended
11.2 No Development Reported
11.3 Discontinued

Competitive Landscape
12.1 Advaxis
12.2 AlphaVax
12.3 AVAX Technologies
12.4 Dendreon Corporation
12.5 Galena Biopharma
12.6 Generex Biotechnology
12.7 GlaxoSmithKline
12.8 Immune Design
12.9 Imugene
12.10 Immunovative Therapies
12.11 Immunovaccine
12.12 Inovio Pharmaceuticals
12.13 Merck
12.14 NewLink Genetics
12.15 Recombio
12.16 TapImmune
12.17 ViroMed

Download Report: https://www.kuickresearch.com/report-global-breast-cancer-vaccine-market-and-clinical-pipeline-outlook-2022.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.